Target Validation Information
Target ID T53524
Target Name Alpha platelet-derived growth factor receptor
Target Type
Successful
Drug Potency against Target RPR-108514A Drug Info IC50 = 15000 nM
PD-0173952 Drug Info IC50 = 636 nM [525862]
PD-0166326 Drug Info IC50 = 139 nM [525862]
Ro-4396686 Drug Info IC50 = 83 nM [528018]
JNJ-10198409 Drug Info IC50 = 45 nM [527932]
(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone Drug Info IC50 = 200 nM [528209]
7-Chloro-3-pyridin-4-yl-quinoline Drug Info IC50 = 300 nM [533872]
5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol Drug Info IC50 = 600 nM [527769]
PD-0173955 Drug Info IC50 = 1660 nM [525862]
PD-0180970 Drug Info IC50 = 1430 nM [525862]
SEMAXINIB Drug Info IC50 = 4050 nM [526575]
3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline Drug Info IC50 = 25 nM [533862]
6,7-Difluoro-3-thiophen-3-yl-quinoline Drug Info IC50 = 4000 nM [533862]
7-Fluoro-3-thiophen-3-yl-quinoline Drug Info IC50 = 25 nM [533862]
5,7-Dimethoxy-3-pyridin-4-yl-quinoline Drug Info Ki = 14 nM [533872]
3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline Drug Info IC50 = 600 nM [533862]
6,7-Dimethoxy-3-p-tolyl-quinoline Drug Info IC50 = 2000 nM [533862]
6,7-Dimethoxy-3-phenyl-quinoline Drug Info IC50 = 150 nM [533862]
3-Cyclohexylethynyl-6,7-dimethoxy-quinoline Drug Info IC50 = 1000 nM [533862]
AG1295 Drug Info IC50 = 5400 nM [528209]
(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone Drug Info IC50 = 760 nM [528209]
Di(1H-indol-2-yl)methanone Drug Info IC50 = 1000 nM [528209]
1-Phenyl-1H-benzoimidazole Drug Info IC50 = 2300 nM [534808]
4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline Drug Info IC50 = 70 nM
SU-11652 Drug Info IC50 < 70 nM [526575]
(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone Drug Info IC50 = 10000 nM [528209]
Bis-(5-hydroxy-1H-indol-2-yl)-methanone Drug Info IC50 = 300 nM [528209]
(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone Drug Info IC50 = 300 nM [528209]
3-Pyridin-3-yl-quinoline-6,7-diol Drug Info IC50 = 10000 nM [533862]
PD-0179483 Drug Info IC50 = 463 nM [525862]
3-Pyridin-4-yl-quinolin-7-ol Drug Info IC50 = 9200 nM [533872]
Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine Drug Info IC50 = 80 nM [533862]
4-Benzoimidazol-1-yl-phenylamine Drug Info IC50 = 2000 nM [534808]
6,7-Dimethoxy-3-pyridin-4-yl-quinoline Drug Info IC50 = 300 nM [533872]
3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline Drug Info IC50 = 60 nM [533862]
3-Pyridin-4-yl-quinoline Drug Info IC50 = 1500 nM [533872]
3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline Drug Info IC50 = 200 nM [533862]
3-(1H-Indol-3-yl)-quinoline Drug Info IC50 = 8000 nM [533862]
5,7-Dimethyl-3-thiophen-3-yl-quinoline Drug Info IC50 = 5 nM [533862]
3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline Drug Info IC50 = 10000 nM [533862]
7-Methoxy-3-thiophen-3-yl-quinoline Drug Info IC50 = 60 nM [533862]
4-(6,7-Dimethoxy-quinolin-3-yl)-phenol Drug Info IC50 = 30 nM [533862]
6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline Drug Info IC50 = 15 nM [533862]
7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline Drug Info IC50 = 600 nM [533862]
3-Thiophen-3-yl-quinoline Drug Info IC50 = 250 nM [533862]
TAK-593 Drug Info IC50 = 4.3~13 nM
4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine Drug Info IC50 = 1360 nM [525530]
6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline Drug Info IC50 = 2000 nM [533862]
3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline Drug Info IC50 = 500 nM [533862]
3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline Drug Info IC50 = 7000 nM [533862]
(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone Drug Info IC50 = 300 nM [528209]
5-Methoxy-1-phenyl-1H-benzoimidazole Drug Info IC50 = 1900 nM [534808]
3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline Drug Info IC50 = 40 nM [533862]
6-Methoxy-3-pyridin-4-yl-quinoline Drug Info IC50 = 400 nM [533872]
RG-13022 Drug Info IC50 = 3000 nM [533862]
6,7-Dichloro-3-thiophen-3-yl-quinoline Drug Info IC50 = 2000 nM [533862]
3-Cyclopentyl-6,7-dimethoxy-quinoline Drug Info IC50 = 500 nM [533862]
5-Fluoro-3-thiophen-3-yl-quinoline Drug Info IC50 = 20 nM [533862]
5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one Drug Info IC50 = 30 nM [533862]
4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid Drug Info IC50 = 5000 nM [533862]
6,7-Dimethoxy-3-thiophen-2-yl-quinoline Drug Info IC50 = 80 nM [533862]
5,7-Dimethoxy-3-thiophen-3-yl-quinoline Drug Info IC50 = 30 nM [533862]
3-Pyridin-4-yl-quinoline-5,7-diol Drug Info IC50 = 1300 nM [533872]
5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline Drug Info IC50 = 400 nM [533872]
RPR-101511 Drug Info IC50 = 20 nM [533862]
6-Methoxy-3-thiophen-3-yl-quinoline Drug Info IC50 = 70 nM [533862]
7-Methoxy-3-pyridin-4-yl-quinoline Drug Info IC50 = 600 nM [533872]
6,7-Dimethoxy-3-pyridin-3-yl-quinoline Drug Info IC50 = 800 nM [533862]
3-((E)-Styryl)-quinoline Drug Info IC50 = 200 nM [533862]
6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline Drug Info IC50 = 2000 nM [533862]
1-Phenyl-1H-benzoimidazol-5-ol Drug Info IC50 = 130 nM [534808]
6,7-Dimethoxy-3-phenylethynyl-quinoline Drug Info IC50 = 50 nM [533862]
6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline Drug Info IC50 = 150 nM [533862]
3-Benzyloxy-6,7-dimethoxy-quinoline Drug Info IC50 = 70 nM [533862]
6,7-Dimethoxy-3-((E)-styryl)-quinoline Drug Info IC50 = 5 nM [533862]
PD-0173956 Drug Info IC50 = 1250 nM [525862]
PD-0173958 Drug Info IC50 = 2340 nM [525862]
Action against Disease Model TAK-593 TAK-593 acts on the colorectal cancer cell lines that were analysed revealed varying expression intensities of PDGFRalpha and PDGFRbeta. [552784] Drug Info
The Effect of Target Knockout, Knockdown or Genetic Variations The mechanisms facilitating viral entry and gene expression are not clearly understood. Here we show that platelet-derived growth factor-alpha receptor (PDGFR-alpha) is specifically phosphorylated by both laboratory and clinical isolates of HCMV in various h uMan cell types, resulting in activation of the phosphoinositide-3-kinase (PI(3)K) signalling pathway. Upon stimulation by HCMV, tyrosine-phosphorylated PDGFR-alpha associated with the p85 regulatory subunit of PI(3)K and induced protein kinase B (also known as Akt) phosphorylation, similar to the genuine ligand, PDGF-AA. Cells in which PDGFR-alpha was genetically deleted or functionally blocked were non-permissive to HCMV entry, viral gene expression or infectious virus production. Re-introducing h uMan PDGFRA gene into knockout cells restored susceptibility to viral entry and essential viral gene expression. Blockade of receptor function with a h uManized PDGFR-alpha blocking antibody (IMC-3G3) or targeted inhibition of its kinase activity with a small molecule (Gleevec) completely inhibited HCMV viral internalization and gene expression in h uMan epithelial, endothelial and fibroblast cells. Viral entry in cells harbouring endogenous PDGFR-alpha was competitively inhibited by pretreatment with PDGF-AA. We further demonstrate that HCMV glycoprotein B directly interacts with PDGFR-alpha, resulting inreceptor tyrosine phosphorylation, and that glycoprotein B neutralizing antibodies inhibit H uMan cytomegalovirus-induced PDGFR-alpha phosphorylation. Taken together, these data indicate that PDGFR-alpha is a critical receptor required for HCMV infection, and thus a target for novel anti-viral therapies.
References
Ref 525862Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
Ref 525862Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
Ref 528018Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. Epub 2006 Feb 3.Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.
Ref 527932J Med Chem. 2005 Dec 29;48(26):8163-73.(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 527769J Med Chem. 2005 Oct 6;48(20):6194-201.Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
Ref 525862Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
Ref 525862Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
Ref 526575J Med Chem. 2003 Mar 27;46(7):1116-9.Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
Ref 552784PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol Rep. 2008 Mar;19(3):697-704.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 534808J Med Chem. 1998 Dec 31;41(27):5457-65.Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
Ref 526575J Med Chem. 2003 Mar 27;46(7):1116-9.Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 525862Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 534808J Med Chem. 1998 Dec 31;41(27):5457-65.Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 525530J Med Chem. 1999 Jul 1;42(13):2373-82.Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 534808J Med Chem. 1998 Dec 31;41(27):5457-65.Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533872J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 534808J Med Chem. 1998 Dec 31;41(27):5457-65.Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 533862J Med Chem. 1994 Jul 8;37(14):2129-37.A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.
Ref 525862Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
Ref 525862Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.